Moreover, we have demonstrated that a Rho-kinase/ROCK inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells [24], thereby indicating that ROCK might be considered as a new therapeutic target for colon cancer patients. Here, AKT1 is linked to malignant colon neoplasm.